» Articles » PMID: 37990425

Radioprotective Potency of Nanoceria

Overview
Journal Curr Radiopharm
Date 2023 Nov 22
PMID 37990425
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer presents a significant medical challenge that requires effective management. Current cancer treatment options, such as chemotherapy, targeted therapy, radiotherapy, and immunotherapy, have limitations in terms of their efficacy and the potential harm they can cause to normal tissues. In response, researchers have been focusing on developing adjuvants that can enhance tumor responses while minimizing damage to healthy tissues. Among the promising options, nanoceria (NC), a type of nanoparticle composed of cerium oxide, has garnered attention for its potential to improve various cancer treatment regimens. Nanoceria has demonstrated its ability to exhibit toxicity towards cancer cells, inhibit invasion, and sensitize cancer cells to both radiation therapy and chemotherapy. The remarkable aspect is that nanoceria show minimal toxicity to normal tissues while protecting against various forms of reactive oxygen species generation. Its capability to enhance the sensitivity of cancer cells to chemotherapy and radiotherapy has also been observed. This paper thoroughly reviews the current literature on nanoceria's applications within different cancer treatment modalities, with a specific focus on radiotherapy. The emphasis is on nanoceria's unique role in enhancing tumor radiosensitization and safeguarding normal tissues from radiation damage.

Citing Articles

Lipid Coating Modulates Effects of Nanoceria on Oxidative Metabolism in Human Embryonic Lung Fibroblasts: A Case of Cardiolipin.

Proskurnina E, Sozarukova M, Ershova E, Savinova E, Kameneva L, Veiko N Biomolecules. 2025; 15(1).

PMID: 39858447 PMC: 11764243. DOI: 10.3390/biom15010053.

References
1.
Barrios C . Global challenges in breast cancer detection and treatment. Breast. 2022; 62 Suppl 1:S3-S6. PMC: 9097801. DOI: 10.1016/j.breast.2022.02.003. View

2.
Baskar R, Lee K, Yeo R, Yeoh K . Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012; 9(3):193-9. PMC: 3298009. DOI: 10.7150/ijms.3635. View

3.
Choi W, Cho J . Evolving Clinical Cancer Radiotherapy: Concerns Regarding Normal Tissue Protection and Quality Assurance. J Korean Med Sci. 2016; 31 Suppl 1:S75-87. PMC: 4756347. DOI: 10.3346/jkms.2016.31.S1.S75. View

4.
Elbanna M, Chowdhury N, Rhome R, Fishel M . Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy. Front Oncol. 2021; 11:749496. PMC: 8558533. DOI: 10.3389/fonc.2021.749496. View

5.
Shaghaghi Z, Alvandi M, Nosrati S, Hadei S . Potential utility of peptides against damage induced by ionizing radiation. Future Oncol. 2021; 17(10):1219-1235. DOI: 10.2217/fon-2020-0577. View